Silver Book Fact

Effects of optimal anticoagulation among AFib patients

If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.

Caro J. An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation. Am J Managed Care. 2004; 10(14): S451-61. https://www.ajmc.com/view/dec04-1992ps451-s461

Reference

Title
An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation
Publication
Am J Managed Care
Publication Date
2004
Authors
Caro J
Volume & Issue
Volume 10, Issue 14
Pages
S451-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.  
  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…